Adaptimmune Therapeutics PLC Files 8-K
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 8-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $156,086, $472,131, $20,310.20, $1.35273 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-statements, filing
Related Tickers: ADAP
TL;DR
Adaptimmune filed an 8-K on 8/29/25 covering director changes and financials.
AI Summary
Adaptimmune Therapeutics PLC filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate governance changes and the release of financial information, which are crucial for investors to assess the company's stability and performance.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate governance and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
FAQ
What specific items are covered in the 8-K filing by Adaptimmune Therapeutics PLC?
The 8-K filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is August 29, 2025.
What is the company's jurisdiction of incorporation?
The company's jurisdiction of incorporation is England and Wales.
What is the Standard Industrial Classification (SIC) code for Adaptimmune Therapeutics PLC?
The Standard Industrial Classification (SIC) code for Adaptimmune Therapeutics PLC is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the fiscal year end for Adaptimmune Therapeutics PLC?
The fiscal year end for Adaptimmune Therapeutics PLC is December 31.
Filing Stats: 1,124 words · 4 min read · ~4 pages · Grade level 12 · Accepted 2025-08-29 16:30:45
Key Financial Figures
- $156,086 — to 115,386 (equivalent to approximately $156,086*) and reimbursement of healthcare benef
- $472,131 — base salary for 2025, in the amount of $472,131, less all applicable deductions and wit
- $20,310.20 — ciliation Act of 1985 ( COBRA) totaling $20,310.20. These payments will be made in lump-su
- $1.35273 — terling/U.S. dollar exchange rate of (1/$1.35273). Item 9.01 Financial Statements and E
Filing Documents
- adap-20250829x8k.htm (8-K) — 41KB
- adap-20250829xex10d1.htm (EX-10.1) — 23KB
- adap-20250829xex10d2.htm (EX-10.2) — 42KB
- adap-20250829xex10d1001.jpg (GRAPHIC) — 2KB
- adap-20250829xex10d1002.jpg (GRAPHIC) — 9KB
- adap-20250829xex10d1005.jpg (GRAPHIC) — 4KB
- adap-20250829xex10d1006.jpg (GRAPHIC) — 1KB
- 0001558370-25-011820.txt ( ) — 256KB
- adap-20250829.xsd (EX-101.SCH) — 4KB
- adap-20250829_lab.xml (EX-101.LAB) — 16KB
- adap-20250829_pre.xml (EX-101.PRE) — 11KB
- adap-20250829x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 10.1 Variation Letter Agreement dated as of August 29, 2025 by and between Adaptimmune Therapeutics plc and Gavin Wood. 10.2 Separation Agreement dated as of August 29, 2025 by and between Adaptimmune, LLC and John Lunger. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date: August 29, 2025 By: /s/ Margaret Henry Name: Margaret Henry Title: Corporate Secretary